The FDA has approved Jardiance (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and older with… read more.
People who develop diabetes following pregnancy were significantly less likely to be able to bring it under control if they had experienced gestational diabetes during their pregnancy, especially… read more.
An investigator with the University of Kansas School of Pharmacy has filed an invention disclosure, part of a provisional patent application with the United States Patent and Trademark… read more.
A research team led by the Complexity Science Hub Vienna and the Medical University of Vienna has analysed the actual prevalence of Type 2 diabetes in Austria for… read more.
A new substudy of the STEP TEENS trial presented at this year’s European Congress on Obesity (ECO 2023, Dublin 17-20 May) shows that adolescents using semaglutide experienced significant… read more.
In a small feasibility study, subjects with type 2 diabetes achieved significant improvement in long-term blood sugar levels following treatment with high-dose tadalafil, an erectile dysfunction drug. Tadalafil… read more.
Alex Miras is Professor of Endocrinology at the University of Ulster, UK and is an expert in obesity management and research. In 2021 a trial of semaglutide for… read more.
Professor Alex Miras, consultant endocrinologist at the University of Ulster, takes the view that obesity is a disease. He explains why this is and how the SELECT trial… read more.
GLP1 receptor agonists — a class of diabetes medications — are associated with fewer major adverse cardiovascular events than another type of diabetes drug (DPP4 inhibitors) in older… read more.
Semaglutide works well on its own as obesity treatment but it works even better with the support and guidance of a multi-disciplinary weight-management team, according to Alex Miras,… read more.
In March 2023 the National Institute for Health and Care Excellence (NICE) published Technology Appraisal Guidance for semaglutide for obesity. Professor Alex Miras explains the guidance and its… read more.
Alex Miras is Professor of Endocrinology at the University of Ulster, UK and is an expert in obesity management and research. In 2021 a trial of semaglutide for… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
